Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma-Reference-Cited by-同舟云学术

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

Published:2023-01 Issue:1 Volume:5 Page:100620
ISSN:2589-5559
Container-title:JHEP Reports
language:en
Short-container-title:JHEP Reports

Author:

Scheiner Bernhard^ORCID,Roessler Daniel,Phen Samuel,Lim Mir^ORCID,Pomej Katharina^ORCID,Pressiani Tiziana,Cammarota Antonella^ORCID,Fründt Thorben W.,von Felden Johann,Schulze Kornelius,Himmelsbach Vera,Finkelmeier Fabian,Deibel Ansgar^ORCID,Siebenhüner Alexander R.,Shmanko Kateryna,Radu Pompilia,Schwacha-Eipper Birgit,Ebert Matthias P.,Teufel Andreas,Djanani Angela,Hucke Florian^ORCID,Balcar Lorenz^ORCID,Philipp Alexander B.^ORCID,Hsiehchen David,Venerito Marino^ORCID,Sinner Friedrich^ORCID,Trauner Michael,D'Alessio Antonio^ORCID,Fulgenzi Claudia A.M.,Pinato David J.^ORCID,Peck-Radosavljevic Markus^ORCID,Dufour Jean-François,Weinmann Arndt^ORCID,Kremer Andreas E.^ORCID,Singal Amit G.^ORCID,De Toni Enrico N.,Rimassa Lorenza^ORCID,Pinter Matthias^ORCID

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Immunology and Allergy,Internal Medicine

Reference17 articles.

1. Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Systemic treatment of hepatocellular carcinoma: an EASL position paper;Bruix;J Hepatol,2021

3. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review;Pinter;JAMA Oncol,2021

4. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020

5. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline;Gordan;J Clin Oncol,2020

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment;Targeted Oncology;2024-09

2. Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma;Investigational New Drugs;2024-08-30

3. Real-world efficacy and safety of durvalumab–tremelimumab as second-line systemic therapy after atezolizumab–bevacizumab in unresectable hepatocellular carcinoma;Medicine;2024-08-23

4. The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma;Journal of Clinical Medicine;2024-08-23

5. Efficacy and Safety of Durvalumab Rechallenge in Advanced Hepatocellular Carcinoma Patients Refractory to Prior Anti-PD-1 Therapy;2024-08-09